

Table S1: Puberty and previous treatment status of the non-treatment-naïve/prepubertal subgroups (Enrolled population)

Treatment status	Non-NPP-Laron syndrome (N = 17)	Non-NPP-non-Laron syndrome (N = 87)
Pubertal naïve	6%	25%
Pubertal non-naïve	38%	18%
GH	33%	93%
rhIGF-1	100%	27%
Steroids	-	20%
GH and rhIGF-1	33%	20%
Prepubertal non-naïve	56%	58%
GH	33%	94%
rhIGF-1	67%	14%
GH and rhIGF-1	-	8%
Steroids	-	2%

Naïve patients are defined as patients without previous growth promoting therapy except corticosteroids. Patients treated with both GH and IGF-1 are also counted in the separate GH and rhIGF-1 categories. GH, growth hormone; IGF-1; insulin-like growth factor-1; non-NPP, not treatment naïve and/or pubertal.